Those questions, experts say, are based on the Trump administration’s hawkish approach to China generally, as well as on a ...

The elimination of 3,500 full-time employees at the FDA risks undermining the very innovation and domestic capacity the ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Review of foreign scientists from countries like China began even before three Chinese scientists in Michigan were caught ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

From an office a 15-minute drive from Chicago's O'Hare International Airport, one small firm helped import millions of ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

Food and Drug Administration staff cuts may hinder US biomedical innovation by Former Rep. John T. Doolittle (R-Calif.), opinion contributor - 06/22/25 12:00 PM ET ...

EY life sciences leader Arda Ural is among those watching and said that China is no longer the land of generics and active pharmaceutical ingredients (APIs) used by the rest of th ...